Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

bio-techne corp. - TECH

TECH

Close Chg Chg %
72.74 0.29 0.40%

Pre-Market

73.03

+0.29 (0.40%)

Volume: 309.62K

Last Updated:

Dec 24, 2024, 1:00 PM EDT

Trade Now

Company Overview: bio-techne corp. - TECH

TECH Key Data

Open

$72.63

 Day Range

72.49 - 73.38

52 Week Range

61.16 - 85.57

 Market Cap

$11.60B

Shares Outstanding

158.89M

 Public Float

157.23M

Beta

1.26

 Rev. Per Employee

N/A

P/E Ratio

77.83

 EPS

$0.96

Yield

43.82%

 Dividend

$0.08

EX-DIVIDEND DATE

Nov 8, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

772.24K

  

TECH Performance

1 Week
 
 -0.19%
 
1 Month
 
 -3.09%
 
3 Months
 
 -7.23%
 
1 Year
 
 -5.35%
 
5 Years
 
 33.80%
 

TECH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About bio-techne corp. - TECH

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

TECH At a Glance

Bio-Techne Corp.
614 McKinley Place NE
Minneapolis, Minnesota 55413-2610
Phone 1-612-379-8854 Revenue 1.16B
Industry Biotechnology Net Income 168.07M
Sector Health Technology 2024 Sales Growth 1.967%
Fiscal Year-end 06 / 2025 Employees 3,100
View SEC Filings

TECH Valuation

P/E Current 77.832
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 68.538
Price to Sales Ratio 9.939
Price to Book Ratio 5.479
Price to Cash Flow Ratio 38.529
Enterprise Value to EBITDA 32.312
Enterprise Value to Sales 10.169
Total Debt to Enterprise Value 0.036

TECH Efficiency

Revenue/Employee 373,890.323
Income Per Employee 54,216.774
Receivables Turnover 4.802
Total Asset Turnover 0.418

TECH Liquidity

Current Ratio 3.874
Quick Ratio 2.746
Cash Ratio 0.959

TECH Profitability

Gross Margin 66.698
Operating Margin 21.832
Pretax Margin 16.021
Net Margin 14.501
Return on Assets 6.06
Return on Equity 8.33
Return on Total Capital 6.754
Return on Invested Capital 6.88

TECH Capital Structure

Total Debt to Total Equity 20.279
Total Debt to Total Capital 16.86
Total Debt to Total Assets 14.913
Long-Term Debt to Equity 19.654
Long-Term Debt to Total Capital 16.341
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bio-techne Corp. - TECH

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
931.03M 1.11B 1.14B 1.16B
Sales Growth
+26.04% +18.75% +2.81% +1.97%
Cost of Goods Sold (COGS) incl D&A
326.58M 382.60M 366.89M 385.99M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
87.75M 101.07M 107.24M 111.71M
Depreciation
22.81M 26.92M 29.75M 31.86M
Amortization of Intangibles
64.94M 74.15M 77.49M 79.85M
COGS Growth
+15.77% +17.15% -4.11% +5.21%
Gross Income
604.45M 723.00M 769.82M 773.07M
Gross Income Growth
+32.38% +19.61% +6.48% +0.42%
Gross Profit Margin
+64.92% +65.39% +67.72% +66.70%
2021 2022 2023 2024 5-year trend
SG&A Expense
354.62M 445.53M 489.11M 520.02M
Research & Development
70.60M 87.14M 92.49M 96.66M
Other SG&A
284.01M 358.39M 396.61M 423.36M
SGA Growth
+18.37% +25.64% +9.78% +6.32%
Other Operating Expense
- - - 900.00K
-
Unusual Expense
80.59M (35.21M) (67.56M) 46.08M
EBIT after Unusual Expense
169.25M 311.78M 348.27M 206.97M
Non Operating Income/Expense
1.48M 7.27M 5.05M 7.98M
Non-Operating Interest Income
473.00K 794.00K 3.41M 3.32M
Equity in Earnings of Affiliates
- - - (6.84M)
-
Interest Expense
22.55M 17.66M 14.67M 29.26M
Interest Expense Growth
+53.46% -21.68% -16.95% +99.50%
Gross Interest Expense
22.55M 17.66M 14.67M 29.26M
Interest Capitalized
- - - -
-
Pretax Income
148.18M 301.39M 338.66M 185.69M
Pretax Income Growth
-46.41% +103.40% +12.37% -45.17%
Pretax Margin
+15.92% +27.26% +29.79% +16.02%
Income Tax
8.59M 38.29M 53.22M 17.58M
Income Tax - Current - Domestic
21.86M 16.74M 72.56M 45.08M
Income Tax - Current - Foreign
14.74M 14.48M 10.45M 12.66M
Income Tax - Deferred - Domestic
(25.77M) 9.61M (31.24M) (32.86M)
Income Tax - Deferred - Foreign
(2.24M) (2.54M) 1.44M (7.30M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - (6.84M)
-
Other After Tax Income (Expense)
(86.00K) (121.00K) (70.00K) (33.00K)
Consolidated Net Income
139.50M 262.98M 285.37M 168.07M
Minority Interest Expense
- (825.00K) (8.95M) 179.00K
Net Income
140.32M 271.93M 285.19M 168.07M
Net Income Growth
-38.74% +93.79% +4.88% -41.07%
Net Margin Growth
+15.07% +24.60% +25.09% +14.50%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
140.32M 271.93M 285.19M 168.07M
Preferred Dividends
- - - -
-
Net Income Available to Common
140.32M 271.93M 285.19M 168.07M
EPS (Basic)
0.9054 1.7334 1.8144 1.0657
EPS (Basic) Growth
-39.60% +91.45% +4.67% -41.26%
Basic Shares Outstanding
154.99M 156.88M 157.18M 157.71M
EPS (Diluted)
0.8666 1.6569 1.762 1.0454
EPS (Diluted) Growth
-40.38% +91.20% +6.34% -40.67%
Diluted Shares Outstanding
161.93M 164.12M 161.85M 160.77M
EBITDA
337.58M 377.63M 387.95M 364.76M
EBITDA Growth
+40.80% +11.86% +2.73% -5.98%
EBITDA Margin
+36.26% +34.16% +34.13% +31.47%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 83.167
Number of Ratings 18 Current Quarters Estimate 0.387
FY Report Date 12 / 2024 Current Year's Estimate 1.878
Last Quarter’s Earnings 0.42 Median PE on CY Estimate N/A
Year Ago Earnings 1.77 Next Fiscal Year Estimate 2.183
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 14 13
Mean Estimate 0.39 0.52 1.88 2.18
High Estimates 0.40 0.54 1.94 2.37
Low Estimate 0.36 0.48 1.78 1.99
Coefficient of Variance 3.97 2.77 2.31 4.90

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 10 10
OVERWEIGHT 4 3 2
HOLD 4 4 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Bio-techne Corp. - TECH

Date Name Shares Transaction Value
Aug 20, 2024 Shane V. Bohnen SVP - General Counsel 13,488 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 William A. Geist PRESIDENT, PROTEIN SCIENCES 21,204 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 William A. Geist PRESIDENT, PROTEIN SCIENCES 7,869 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 William A. Geist PRESIDENT, PROTEIN SCIENCES 15,738 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Shane V. Bohnen SVP - General Counsel 1,681 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $74.91 per share 125,923.71
Aug 20, 2024 Shane V. Bohnen SVP - General Counsel 99 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 James T. Hippel CFO 32,417 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 James T. Hippel CFO 12,031 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 James T. Hippel CFO 24,062 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Matthew F. McManus President - DGS 21,320 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Matthew F. McManus President - DGS 7,912 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Matthew F. McManus President - DGS 15,818 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Shane V. Bohnen SVP - General Counsel 1,696 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 20, 2024 Kim Kelderman Chief Executive Officer; Director 69,061 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Kim Kelderman Chief Executive Officer; Director 25,630 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Kim Kelderman Chief Executive Officer; Director 51,261 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Shane V. Bohnen SVP - General Counsel 10,012 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 20, 2024 Shane V. Bohnen SVP - General Counsel 5,006 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 26, 2024 James T. Hippel CFO 107,284 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $31.26 per share 3,353,697.84
Jul 26, 2024 James T. Hippel CFO 83,002 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $77.77 per share 6,455,065.54

Bio-Techne Corp. in the News